Floatz logo

immunoglobulin H-gamma1_L-kappa, anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3) and anti-[Homo sapiens DLL3 (delta-like ligand 3, delta like canonical Notch ligand 3)], bispecific;

Neuroendocrine Carcinomas (NEC)

Phanes Therapeuticsmonoclonal_antibodyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

49 Active assets in the Neuroendocrine Carcinomas (NEC) cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2B
Everolimus
AIO-Studien-gGmbH
Phase 2B
Lurbinectedin
Jazz Pharmaceuticals
Phase 2B
Octreotide Pamoate
Novartis Pharmaceuticals
Phase 2B

View all 50 →

Same molecule, other indications

immunoglobulin H-gamma1_L-kappa, anti-[Homo sapiens CD47 (CD47 molecule, integrin associated protein, IAP, MER6, OA3) and anti-[Homo sapiens DLL3 (delta-like ligand 3, delta like canonical Notch ligand 3)], bispecific; is also rated in:

large cell neuroendocrine carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
prostate neuroendocrine neoplasmDormant
CC
Indicative ·
47 / 100
View asset →
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)Dormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →